NCT04838171

Brief Summary

The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
45mo left

Started Mar 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Mar 2021Jan 2030

Study Start

First participant enrolled

March 24, 2021

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

April 1, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 8, 2021

Completed
8.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

January 21, 2026

Status Verified

January 1, 2026

Enrollment Period

8.8 years

First QC Date

April 1, 2021

Last Update Submit

January 16, 2026

Conditions

Autoimmune DiseasesInflammationRejection; Transplant, Liver

Outcome Measures

Primary Outcomes (1)

  • WBC characterisation to support the development of engineered regulatory T cells.

    number, type and function of white blood cells in healthy controls and in patients

    5 years

Study Arms (1)

Specimen collection to support development of engineering Treg

Other: White blood cell and blood collection

Interventions

White blood cell and blood collectionOTHER

Mononucleocytes will be collected via apheresis

Specimen collection to support development of engineering Treg

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Volunteers willing to provide white blood cells for research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Quell Investigator Site 01

London, United Kingdom

RECRUITING

MeSH Terms

Conditions

Autoimmune DiseasesInflammationRejection, Psychology

Interventions

Leukocyte Count

Condition Hierarchy (Ancestors)

Immune System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSocial BehaviorBehavior

Intervention Hierarchy (Ancestors)

Blood Cell CountCell CountCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHematologic TestsInvestigative TechniquesCell Physiological PhenomenaBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Central Study Contacts

Gareth Wright

CONTACT

+4(0)2070969012contact@quell-tx.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 1, 2021

First Posted

April 8, 2021

Study Start

March 24, 2021

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

January 1, 2030

Last Updated

January 21, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

GB(1)